ICNMD 2021 poster: Demographic and safety data from patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving ataluren in the STRIDE Registry
This poster, from the virtual 2021 ICNMD meeting, shows the demographic and safety data for patients included in the STRIDE Registry population
Understand the rationale for the STRIDE Registry, a post-approval study of a mutation-specific Duchenne muscular dystrophy (DMD) therapy
Review the demographics of participants in the STRIDE Registry (n=224), across 11 countries – both for the safety and the efficacy populations
Explore the safety results of the study
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200031 | March 2022
Sign in or register to access exclusive content on this site